GlassScriptPhysician profile
Brian K Adler
NPI 1588774624
$20,636.37
in general payments reported to CMS, 2019-2025
77 companies · $3,667 in 2025
The $3,667 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,514 · 2020: $1,805 · 2021: $2,709 · 2022: $2,631 · 2023: $2,974 · 2024: $3,336 · 2025: $3,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,684 · Consulting Fee: $175 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,683.98 |
| Consulting Fee | $175.00 |
| Education | $119.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,302.93 | 2019-2025 | Polivy, Tecentriq, Venclexta |
| E.R. Squibb & Sons, L.L.C. | $1,219.52 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Janssen Biotech, INC. | $1,114.32 | 2019-2025 | Darzalex, Erleada, Carvykti |
| Pfizer INC. | $1,006.87 | 2019-2025 | |
| Amgen INC. | $953.41 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Astrazeneca Pharmaceuticals LP | $950.69 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $908.36 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Novartis Pharmaceuticals Corporation | $889.81 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $765.85 | 2019-2025 | Ultomiris |
| Abbvie INC. | $751.63 | 2019-2025 | Venclexta, Creon |
| Incyte Corporation | $639.90 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $543.80 | 2019-2025 | Reblozyl, Opdualag, Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $517.78 | 2019-2025 | Fruzaqla, Ninlaro |
| Genzyme Corporation | $492.23 | 2019-2025 | |
| Gilead Sciences, INC. | $486.20 | 2019-2025 | Trodelvy |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $438.04 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Daiichi Sankyo INC. | $396.39 | 2019-2025 | Enhertu, Datroway |
| Deciphera Pharmaceuticals INC. | $395.46 | 2020-2025 | Qinlock, Romvimza |
| Eisai INC. | $388.83 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $356.89 | 2019-2024 | |
| Blueprint Medicines Corporation | $352.69 | 2020-2025 | Ayvakit |
| Lilly USA, LLC | $307.54 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $303.75 | 2020-2025 | Jemperli, Zejula |
| Puma Biotechnology, INC. | $286.96 | 2019-2022 | |
| Csl Behring | $271.80 | 2019-2025 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $270.49 | 2019-2025 | Libtayo, Lynozyfic |
| Beigene USA, INC. | $250.60 | 2020-2025 | Brukinsa, Tevimbra |
| Exelixis INC. | $227.37 | 2019-2025 | Cabometyx |
| Taiho Oncology, INC. | $197.96 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.42 | 2019-2025 | Gilotrif |
| Servier Pharmaceuticals LLC | $169.26 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $163.24 | 2019-2023 | Imbruvica, Epkinly |
| Array Biopharma INC | $160.17 | 2022-2025 | Mektovi, Braftovi, Tukysa |
| Astellas Pharma US INC | $138.57 | 2019-2025 | Xospata, Xtandi, Vyloy |
| Morphosys, US INC. | $133.98 | 2021-2023 | Monjuvi |
| Pharmaessentia USA Corporation | $132.02 | 2023-2025 | Besremi |
| Karyopharm Therapeutics INC. | $127.73 | 2020-2023 | Xpovio |
| Sobi, INC | $122.97 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $121.24 | 2021-2024 | Myrisk, Precisetumor, Bracanalysis Cdx |
| Ipsen Biopharmaceuticals, INC | $116.46 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $116.19 | 2024-2025 | Orgovyx |
| Jazz Pharmaceuticals INC. | $112.66 | 2020-2022 | |
| Octapharma USA, INC. | $104.31 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $103.10 | 2019-2021 | |
| Adaptive Biotechnologies Corporation | $102.73 | 2022-2024 | Clonoseq |
| Dova Pharmaceuticals | $98.63 | 2019-2021 | |
| Genmab U.S., INC. | $85.13 | 2023-2025 | Epkinly |
| Tesaro, INC. | $82.77 | 2019 | |
| Rigel Pharmaceuticals, INC. | $82.47 | 2019-2023 | Tavalisse, Rezlidhia |
| Beone Medicines USA, INC. | $80.16 | 2025 | Brukinsa, Tevimbra |
| Myovant Sciences INC. | $74.62 | 2021-2022 | |
| Coherus Oncology, INC. | $68.38 | 2022-2024 | |
| Clovis Oncology, INC. | $68.07 | 2019-2022 | |
| Emmaus Medical, INC. | $64.44 | 2020-2021 | |
| Helsinn Therapeutics (U.S.), INC. | $61.03 | 2019-2022 | |
| Kite Pharma, INC. | $60.93 | 2019-2022 | |
| Adc Therapeutics America, INC. | $60.47 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $54.83 | 2021-2022 | |
| Emd Serono, INC. | $51.74 | 2019-2022 | |
| Global Blood Therapeutics, INC. | $51.71 | 2020-2022 | |
| Springworks Therapeutics, INC. | $50.63 | 2024-2025 | Ogsiveo |
| Epizyme, INC. | $48.56 | 2021-2022 | |
| Tg Therapeutics, INC. | $43.13 | 2021 | |
| Mirati Therapeutics, INC. | $36.70 | 2023 | Krazati |
| Shire North American Group INC | $35.20 | 2019 | |
| Kyowa Kirin, INC. | $35.20 | 2020 | |
| Verastem, INC. | $33.51 | 2019 | |
| Novocure INC. | $33.15 | 2021 | |
| Spectrum Pharmaceuticals INC. | $30.38 | 2023 | Rolvedon |
| Aveo Pharmaceuticals, INC. | $28.31 | 2025 | |
| Immunogen, INC. | $24.73 | 2023 | Elahere |
| Azurity Pharmaceuticals, INC. | $24.23 | 2025 | Danziten |
| Accord Healthcare, INC. | $22.62 | 2023 | |
| Acrotech Biopharma INC. | $15.13 | 2022 | |
| Acceleron Pharma, INC. | $15.12 | 2021 | |
| Stemline Therapeutics INC. | $13.87 | 2023 | Orserdu |
| Indivior INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
Venclexta $515Keytruda $432Enhertu $369Polivy $297Ultomiris $296Reblozyl $277Darzalex $231Tecentriq $228Fruzaqla $226Hizentra $224Ninlaro $220Opdivo $219Qinlock $212Lenvima $211Monjuvi $209Ayvakit $208Imfinzi $204Orgovyx $198Lunsumio $191Jakafi $191Trodelvy $184Libtayo $181Tukysa $173Lynparza $170Pluvicto $168Brukinsa $163Imbruvica $160Kisqali $159Erleada $158Epkinly $155Xtandi $153Columvi $153Jaypirca $151Scemblix $138Besremi $132Verzenio $130Carvykti $126Padcev $121Opdualag $117Adcetris $112Elrexfio $111Talzenna $109Mektovi $107Braftovi $107Calquence $94.73Tibsovo $93.79Krazati $93.57Ibrance $93.50Talvey $91.26Bosulif $89.08Tecvayli $89.07Elahere $88.54Balversa $88.42Akeega $88.42Welireg $85.08Inlyta $84.68Cabometyx $84.17Romvimza $82.56Clonoseq $81.40Lonsurf $78.02Inqovi $78.02Rybrevant $72.17Xofigo $71.87Nubeqa $71.87Jemperli $63.91Datroway $61.40Pemazyre $59.53Sarclisa $59.41Lumakras $56.46Tevimbra $54.33Fabhalta $53.91Lorbrena $52.27Rezlidhia $50.94Tavalisse $50.94Gilotrif $49.61Xospata $45.50Oxbryta $44.43Vonjo $43.49Doptelet $42.65Zejula $41.94Retevmo $40.71Kyprolis $39.99Udenyca $39.66Promacta $37.63Ogsiveo $36.77Creon $35.92Tasigna $31.78Voranigo $31.35Comirnaty $30.99Gazyva $30.61Lynozyfic $30.44Rolvedon $30.38Lutathera $29.94Xalkori $28.95Fotivda $28.31Vyloy $25.50Danziten $24.23Myrisk $24.09Precisetumor $24.07Hympavzi $23.50
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.